Developer docs
API playgroundTry for free, no card

Search company profiles

Shuttle Pharmaceuticals

Full company profile

uuid00007zz

Namestring
Shuttle Pharmaceuticals
Legal namestring
Shuttle Pharmaceuticals Holdings, Inc.
Company typeenum
Public
Founded yearint
2013
Descriptiontext

Shuttle Pharmaceuticals Holdings, Inc. is a publicly traded micro-cap pharmaceutical and digital infrastructure company headquartered in Gaithersburg, Maryland, listed on NASDAQ under ticker SHPH. Originally founded in 2012-2013 as a cancer treatment and radiation therapy development company, Shuttle has pivoted its business model through two recent acquisitions: the November 2025 acquisition of Canadian AI company Molecule.ai for $8 million, and the May 2026 acquisition of Dogecoin mining company United Dogecoin Inc., supported by approximately $11 million in PIPE financing. The company now operates a dual business model spanning AI-driven drug discovery and cryptocurrency mining.

The Molecule.ai platform, the company's core technology asset, is an AI-driven pharmaceutical software platform for molecular discovery and early-stage drug development. It combines machine learning, generative AI, and predictive analytics with structured scientific workflows, offering capabilities including molecule property prediction, gene-disease pathway analysis, compound interaction prediction, multimodal data processing, and a recently launched next-generation autonomous AI agent system for multi-step reasoning and multi-agent orchestration. The platform targets pharmaceutical companies, biotech firms, and research institutions via direct enterprise sales, though no commercial customers or pricing are disclosed. The United Dogecoin subsidiary is deploying up to 3,000 ElphaPex DG1+ mining rigs at an expected hash rate of approximately 43,200 GH/s, representing roughly 1.5% of global Dogecoin mining capacity, powered by hydroelectric energy secured at $0.064 per kWh, with a strategy of mining and holding DOGE as a treasury asset.

The company's GTM motion relies heavily on capital markets activity, including serial public offerings, private placements, and PIPE financings totaling more than $30 million across 2023-2026, intermediated by WestPark Capital and E.F. Hutton & Co. Management includes interim co-CEO Christopher Cooper (via consulting agreement with Number 2 Capital Corp.), co-CEO Ryan Trasolini (founder of United Dogecoin), and CFO Yuying Liang. The company has undergone a 10-for-1 reverse stock split in June 2026 to comply with Nasdaq listing requirements, reflecting stress signals including a market capitalization of approximately $5.76 million and trading near 52-week lows. No revenue is disclosed and the company exhibits characteristics of an early-stage platform pursuing a turnaround through inorganic expansion.

Short descriptiontext

Shuttle Pharmaceuticals is a publicly traded micro-cap company operating an AI-driven drug discovery platform (Molecule.ai) and a Dogecoin mining subsidiary (United Dogecoin), targeting pharmaceutical researchers and digital asset accumulation through serial acquisitions and equity financings.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersRockville, United States
HQ citystring
Rockville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug discovery, pharmaceutical software platform, molecular discovery software, cancer radiation therapy, cryptocurrency mining operations
Industry1 code
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
AI-driven Pharmaceutical Drug Discovery Software
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1AI Drug Discovery Platform (Molecule.ai)
TypeSubscription Recurring
Description

The company licenses or provides access to its Molecule.ai AI-driven platform for pharmaceutical molecular discovery and drug development, serving biotech and pharmaceutical researchers. Revenue is generated through platform licensing, subscriptions, or usage-based fees for drug discovery services.

shuttlepharma.com
2Dogecoin Mining (United Dogecoin)
TypeHardware Sales
Description

Through its wholly-owned subsidiary United Dogecoin Inc., Shuttle Pharmaceuticals operates Dogecoin mining using ElphaPex DG1+ mining hardware. Revenue is generated from mined DOGE cryptocurrency, which the company intends to hold on its balance sheet as a treasury strategy. Energy costs are secured at competitive rates (hydroelectric at $0.064/kWh).

globenewswire.com
3Capital Markets / Equity Financing
TypeOne Time License
Description

Shuttle Pharmaceuticals raises capital through public offerings of common stock and pre-funded warrants, private placements, and PIPE financings to fund acquisitions, marketing, working capital, and corporate purposes.

shuttlepharma.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1Molecule.ai
Description

AI-driven platform for molecular discovery and early-stage drug development that helps researchers explore chemical space efficiently and evaluate molecular ideas with greater clarity.

stocktitan.net
Core offering1 text field

Shuttle Pharmaceuticals develops and commercializes AI-driven pharmaceutical software for molecular discovery and early-stage drug development through its Molecule.ai platform, with capabilities spanning computational drug design and automated chemistry synthesis. The company also operates cryptocurrency mining through its United Dogecoin Inc. subsidiary and continues legacy work on radiation sensitizer candidates for cancer radiotherapy.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Potential to materially reduce drug development timelines, lower costs, and increase probability of success across the development pipeline
Product overview1 text field

Shuttle Pharmaceuticals operates a dual business model consisting of (1) Molecule.ai, an AI-driven pharmaceutical software platform for molecular discovery and early-stage drug development that helps researchers explore chemical space, evaluate molecular ideas, and identify gene-disease pathway relationships; and (2) United Dogecoin, a wholly-owned subsidiary operating in the cryptocurrency mining sector as a Dogecoin mining company. The company transitioned from its original focus on cancer treatment and radiation therapy development to AI-powered drug discovery and digital asset mining.

Product and service4 records
1Molecule.ai
CategoryAI-driven drug discovery software
Description

AI-driven pharmaceutical software platform for molecular discovery, computational drug design, automated chemistry synthesis, and early-stage drug development, serving pharmaceutical, biotechnology, and research customers.

2RSP-100 Radiation Sensitizer Series (including RSP-150)
CategoryRadiation sensitizer pharmaceutical candidates
Description

Radiation sensitizer drug candidates developed to improve tumor response to radiation therapy in oncology treatment settings, targeted at clinical investigators and oncology research programs.

3United Dogecoin Cryptocurrency Mining Operations
CategoryCryptocurrency mining operations
Description

Cryptocurrency mining operations operated through the United Dogecoin Inc. subsidiary, providing digital asset mining capacity as an additional revenue vertical for the company.

4ShuttleDx
CategoryAI-driven drug discovery software
Description

AI-driven pharmaceutical software offering for molecular discovery and drug development applications, complementing the Molecule.ai platform within Shuttle Pharmaceuticals' software portfolio.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1United Dogecoin Inc.
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-04
Description

Shuttle Pharmaceuticals acquired United Dogecoin Inc. through a definitive merger agreement with a concurrent $11 million PIPE financing. United Dogecoin is a Dogecoin mining company that became a wholly-owned subsidiary of Shuttle. The combined entity aims to become the largest publicly listed Dogecoin mining company by global hashrate percentage, with a strategy of mining Dogecoin and holding mined DOGE on its balance sheet. E.F. Hutton & Co. served as exclusive M&A advisor and placement agent.

stocktitan.net
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-02-02
Description

Shuttle Pharmaceuticals settled liabilities with Theradex Systems for $300,000 as part of its ongoing corporate and financial obligations.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-01-13
Description

Utah launched a pilot program through the state's Office of Artificial Intelligence Policy powered by Doctronic for AI-based prescription refills without physician involvement. Shuttle Pharma positioned this initiative as validation of the broader shift toward AI automation in healthcare, relevant to the company's AI-driven drug discovery and radiotherapy capabilities.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-21
Description

Shuttle Pharmaceuticals completed the acquisition of Canadian AI company Molecule.ai for $8 million (including cash, stock, and contingent payments based on milestones). Molecule.ai's platform utilizes advanced machine learning models to accelerate therapeutic development. The acquisition aims to enhance Shuttle's technological capabilities in drug development and precision radiotherapy solutions, expanding the company's AI-driven pharmaceutical software portfolio.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Publicly traded digital asset mining and infrastructure company with diversified energy and hosting operations. Comparable to United Dogecoin's mining-plus-data-center strategy.

TypeEmerging player
Description

AI-driven drug discovery platform with end-to-end capabilities from target identification through clinical-stage molecules. Comparable to the predictive and generative AI workflow claims of Molecule.ai.

TypeDirect peer
Description

AI-native pharma company using generative AI and automation for small-molecule drug design and discovery. Closely aligned with Molecule.ai's molecule property prediction and compound interaction capabilities.

TypeDirect peer
Description

Publicly traded crypto mining company with a focus on low-cost energy infrastructure, similar to United Dogecoin's hydroelectric energy strategy. Comparable in operational model and capital markets exposure.

TypeEmerging player
Description

AI-enabled drug discovery platform combining patient data, genomics, and ML to identify therapeutic candidates. Comparable in its use of multimodal data and predictive modeling for early-stage discovery.

TypeDirect peer
Description

AI-driven drug discovery company combining machine learning with high-throughput biology to accelerate early-stage pharma R&D. Comparable to Molecule.ai's stated mission of using AI to compress early-stage drug development timelines.

TypeDirect peer
Description

Publicly traded AI-driven molecular simulation and drug discovery software platform serving pharma and biotech researchers. Most direct publicly listed comparable to Molecule.ai, with a similar licensing/subscription model for computational chemistry and predictive analytics.

TypeEmerging player
Description

AI-driven small-molecule drug discovery company using structure-based deep learning models. Comparable to Molecule.ai's molecular property prediction and compound interaction prediction features.

TypeDirect peer
Description

Largest publicly traded cryptocurrency mining company (Bitcoin). Comparable to United Dogecoin as a publicly listed, capital-markets-driven crypto mining operation, though focused on Bitcoin rather than Dogecoin.

TypeRegional player
Description

Publicly traded Bitcoin mining company with a focus on low-cost, sustainable energy and energy-efficient infrastructure. Comparable to United Dogecoin's strategy of securing low-cost hydroelectric power for crypto mining.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Shuttle Pharmaceuticals

AI-driven Pharmaceutical Drug Discovery Softwareshuttlepharma.com

Shuttle Pharmaceuticals is a publicly traded micro-cap company operating an AI-driven drug discovery platform (Molecule.ai) and a Dogecoin mining subsidiary (United Dogecoin), targeting pharmaceutical researchers and digital asset accumulation through serial acquisitions and equity financings.

What Shuttle Pharmaceuticals does

Shuttle Pharmaceuticals Holdings, Inc. is a publicly traded micro-cap pharmaceutical and digital infrastructure company headquartered in Gaithersburg, Maryland, listed on NASDAQ under ticker SHPH. Originally founded in 2012-2013 as a cancer treatment and radiation therapy development company, Shuttle has pivoted its business model through two recent acquisitions: the November 2025 acquisition of Canadian AI company Molecule.ai for $8 million, and the May 2026 acquisition of Dogecoin mining company United Dogecoin Inc., supported by approximately $11 million in PIPE financing. The company now operates a dual business model spanning AI-driven drug discovery and cryptocurrency mining.

The Molecule.ai platform, the company's core technology asset, is an AI-driven pharmaceutical software platform for molecular discovery and early-stage drug development. It combines machine learning, generative AI, and predictive analytics with structured scientific workflows, offering capabilities including molecule property prediction, gene-disease pathway analysis, compound interaction prediction, multimodal data processing, and a recently launched next-generation autonomous AI agent system for multi-step reasoning and multi-agent orchestration. The platform targets pharmaceutical companies, biotech firms, and research institutions via direct enterprise sales, though no commercial customers or pricing are disclosed. The United Dogecoin subsidiary is deploying up to 3,000 ElphaPex DG1+ mining rigs at an expected hash rate of approximately 43,200 GH/s, representing roughly 1.5% of global Dogecoin mining capacity, powered by hydroelectric energy secured at $0.064 per kWh, with a strategy of mining and holding DOGE as a treasury asset.

The company's GTM motion relies heavily on capital markets activity, including serial public offerings, private placements, and PIPE financings totaling more than $30 million across 2023-2026, intermediated by WestPark Capital and E.F. Hutton & Co. Management includes interim co-CEO Christopher Cooper (via consulting agreement with Number 2 Capital Corp.), co-CEO Ryan Trasolini (founder of United Dogecoin), and CFO Yuying Liang. The company has undergone a 10-for-1 reverse stock split in June 2026 to comply with Nasdaq listing requirements, reflecting stress signals including a market capitalization of approximately $5.76 million and trading near 52-week lows. No revenue is disclosed and the company exhibits characteristics of an early-stage platform pursuing a turnaround through inorganic expansion.

Shuttle Pharmaceuticals firmographics

Firmographics
Name
Shuttle Pharmaceuticals
Legal name
Shuttle Pharmaceuticals Holdings, Inc.
Website
https://shuttlepharma.com
Company type
Public
Founded year
2013
Operating status
Operating
Headcount range
1–10 employees
Short description
Shuttle Pharmaceuticals is a publicly traded micro-cap company operating an AI-driven drug discovery platform (Molecule.ai) and a Dogecoin mining subsidiary (United Dogecoin), targeting pharmaceutical researchers and digital asset accumulation through serial acquisitions and equity financings.
Ownership category
akta.pro rank

Shuttle Pharmaceuticals industry classification

Industry
Product category
AI-driven Pharmaceutical Drug Discovery Software
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • AI drug discovery
  • Pharmaceutical software platform
  • Molecular discovery software
  • Cancer radiation therapy
  • Cryptocurrency mining operations

Where Shuttle Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Rockville
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Shuttle Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. AI Drug Discovery Platform (Molecule.ai): The company licenses or provides access to its Molecule.ai AI-driven platform for pharmaceutical molecular discovery and drug development, serving biotech and pharmaceutical researchers. Revenue is generated through platform licensing, subscriptions, or usage-based fees for drug discovery services.
  2. Dogecoin Mining (United Dogecoin): Through its wholly-owned subsidiary United Dogecoin Inc., Shuttle Pharmaceuticals operates Dogecoin mining using ElphaPex DG1+ mining hardware. Revenue is generated from mined DOGE cryptocurrency, which the company intends to hold on its balance sheet as a treasury strategy. Energy costs are secured at competitive rates (hydroelectric at $0.064/kWh).
  3. Capital Markets / Equity Financing: Shuttle Pharmaceuticals raises capital through public offerings of common stock and pre-funded warrants, private placements, and PIPE financings to fund acquisitions, marketing, working capital, and corporate purposes.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Shuttle Pharmaceuticals product offering

Product offering

Core offering

Shuttle Pharmaceuticals develops and commercializes AI-driven pharmaceutical software for molecular discovery and early-stage drug development through its Molecule.ai platform, with capabilities spanning computational drug design and automated chemistry synthesis. The company also operates cryptocurrency mining through its United Dogecoin Inc. subsidiary and continues legacy work on radiation sensitizer candidates for cancer radiotherapy.

Product overview

Shuttle Pharmaceuticals operates a dual business model consisting of (1) Molecule.ai, an AI-driven pharmaceutical software platform for molecular discovery and early-stage drug development that helps researchers explore chemical space, evaluate molecular ideas, and identify gene-disease pathway relationships; and (2) United Dogecoin, a wholly-owned subsidiary operating in the cryptocurrency mining sector as a Dogecoin mining company. The company transitioned from its original focus on cancer treatment and radiation therapy development to AI-powered drug discovery and digital asset mining.

Differentiator

Problem solved

Functional benefit

Brands

  • Molecule.ai: AI-driven platform for molecular discovery and early-stage drug development that helps researchers explore chemical space efficiently and evaluate molecular ideas with greater clarity.

Products and services

  • Molecule.ai AI-driven pharmaceutical software platform for molecular discovery, computational drug design, automated chemistry synthesis, and early-stage drug development, serving pharmaceutical, biotechnology, and research customers.
  • RSP-100 Radiation Sensitizer Series (including RSP-150) Radiation sensitizer drug candidates developed to improve tumor response to radiation therapy in oncology treatment settings, targeted at clinical investigators and oncology research programs.
  • United Dogecoin Cryptocurrency Mining Operations Cryptocurrency mining operations operated through the United Dogecoin Inc. subsidiary, providing digital asset mining capacity as an additional revenue vertical for the company.
  • ShuttleDx AI-driven pharmaceutical software offering for molecular discovery and drug development applications, complementing the Molecule.ai platform within Shuttle Pharmaceuticals' software portfolio.

Quantifiable outcome

  • Potential to materially reduce drug development timelines, lower costs, and increase probability of success across the development pipeline

Companies that use Shuttle Pharmaceuticals

Customer profile

Segments2 records

Ideal customer profiles2 records

Shuttle Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature6 records

Shuttle Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • United Dogecoin Inc.coreStrategic or Co-development Partner · 4 May 2026Shuttle Pharmaceuticals acquired United Dogecoin Inc. through a definitive merger agreement with a concurrent $11 million PIPE financing. United Dogecoin is a Dogecoin mining company that became a wholly-owned subsidiary of Shuttle. The combined entity aims to become the largest publicly listed Dogecoin mining company by global hashrate percentage, with a strategy of mining Dogecoin and holding mined DOGE on its balance sheet. E.F. Hutton & Co. served as exclusive M&A advisor and placement agent.
  • Theradex SystemsminorStrategic or Co-development Partner · 2 February 2026Shuttle Pharmaceuticals settled liabilities with Theradex Systems for $300,000 as part of its ongoing corporate and financial obligations.
  • Doctronic / Utah Office of Artificial Intelligence PolicyminorStrategic or Co-development Partner · 13 January 2026Utah launched a pilot program through the state's Office of Artificial Intelligence Policy powered by Doctronic for AI-based prescription refills without physician involvement. Shuttle Pharma positioned this initiative as validation of the broader shift toward AI automation in healthcare, relevant to the company's AI-driven drug discovery and radiotherapy capabilities.
  • Molecule.aicoreStrategic or Co-development Partner · 21 November 2025Shuttle Pharmaceuticals completed the acquisition of Canadian AI company Molecule.ai for $8 million (including cash, stock, and contingent payments based on milestones). Molecule.ai's platform utilizes advanced machine learning models to accelerate therapeutic development. The acquisition aims to enhance Shuttle's technological capabilities in drug development and precision radiotherapy solutions, expanding the company's AI-driven pharmaceutical software portfolio.

Scale indicators11 records

Recent moves6 records

Expansion highlights5 records

Shuttle Pharmaceuticals competitors and assessment

Company assessment

Broad incumbents

  • Hut 8: Publicly traded digital asset mining and infrastructure company with diversified energy and hosting operations. Comparable to United Dogecoin's mining-plus-data-center strategy.

Emerging players

  • Insilico Medicine: AI-driven drug discovery platform with end-to-end capabilities from target identification through clinical-stage molecules. Comparable to the predictive and generative AI workflow claims of Molecule.ai.
  • Valo Health: AI-enabled drug discovery platform combining patient data, genomics, and ML to identify therapeutic candidates. Comparable in its use of multimodal data and predictive modeling for early-stage discovery.
  • Atomwise: AI-driven small-molecule drug discovery company using structure-based deep learning models. Comparable to Molecule.ai's molecular property prediction and compound interaction prediction features.

Direct peers

  • Exscientia: AI-native pharma company using generative AI and automation for small-molecule drug design and discovery. Closely aligned with Molecule.ai's molecule property prediction and compound interaction capabilities.
  • Riot Platforms: Publicly traded crypto mining company with a focus on low-cost energy infrastructure, similar to United Dogecoin's hydroelectric energy strategy. Comparable in operational model and capital markets exposure.
  • Recursion Pharmaceuticals: AI-driven drug discovery company combining machine learning with high-throughput biology to accelerate early-stage pharma R&D. Comparable to Molecule.ai's stated mission of using AI to compress early-stage drug development timelines.
  • Schrödinger: Publicly traded AI-driven molecular simulation and drug discovery software platform serving pharma and biotech researchers. Most direct publicly listed comparable to Molecule.ai, with a similar licensing/subscription model for computational chemistry and predictive analytics.
  • Marathon Digital Holdings: Largest publicly traded cryptocurrency mining company (Bitcoin). Comparable to United Dogecoin as a publicly listed, capital-markets-driven crypto mining operation, though focused on Bitcoin rather than Dogecoin.

Regional players

  • CleanSpark: Publicly traded Bitcoin mining company with a focus on low-cost, sustainable energy and energy-efficient infrastructure. Comparable to United Dogecoin's strategy of securing low-cost hydroelectric power for crypto mining.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Shuttle Pharmaceuticals social profiles

Digital presence

Shuttle Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Shuttle Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles6 records

Shuttle Pharmaceuticals subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Shuttle Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Shuttle Pharmaceuticals M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Shuttle Pharmaceuticals

What does Shuttle Pharmaceuticals do?

Shuttle Pharmaceuticals develops and commercializes AI-driven pharmaceutical software for molecular discovery and early-stage drug development through its Molecule.ai platform, with capabilities spanning computational drug design and automated chemistry synthesis. The company also operates cryptocurrency mining through its United Dogecoin Inc. subsidiary and continues legacy work on radiation sensitizer candidates for cancer radiotherapy.

Is Shuttle Pharmaceuticals a public or private company?

Shuttle Pharmaceuticals is a public company. It is classified as public and is currently operating.

When was Shuttle Pharmaceuticals founded?

Shuttle Pharmaceuticals was founded in 2013. It employs 1 to 10 people.

Where is Shuttle Pharmaceuticals based?

Shuttle Pharmaceuticals is headquartered in Rockville, United States, in the North America region.

How does Shuttle Pharmaceuticals make money?

Three revenue lines are on record. AI Drug Discovery Platform (Molecule.ai) is the primary driver. The others are dogecoin Mining (United Dogecoin) and capital Markets / Equity Financing.

Who are Shuttle Pharmaceuticals's main competitors?

Hut 8 is listed as a broad incumbent. Emerging players are Insilico Medicine, Valo Health and Atomwise. Direct peers are Exscientia, Riot Platforms, Recursion Pharmaceuticals, Schrödinger and Marathon Digital Holdings. CleanSpark is listed as a regional player.

Does Shuttle Pharmaceuticals have an API?

No public API is recorded for Shuttle Pharmaceuticals.

What industry is Shuttle Pharmaceuticals in?

Shuttle Pharmaceuticals's product category is AI-driven Pharmaceutical Drug Discovery Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewShuttle Pharmaceuticals Amends PIPE Terms and Issues Warrants for 6.69 Million SharesShuttle Pharmaceuticals amended its securities purchase agreement with certain investors, revising registration deadlines and milestone conditions. The company issued pre-funded warrants to purchase up to 6,693,740 common shares at $0.001 per share, with no additional cash consideration. The amendment reduces the mining rig threshold and sets staged resale registration deadlines.The future of tradingShuttle Pharmaceuticals Delays Quarterly Report Over Change-in-Control AccountingShuttle Pharmaceuticals delayed its Form 10-Q for the quarter ended September 30, 2026, due to a change-in-control analysis. The delay stems from a September 9, 2026 conversion of Series B-1 Preferred Stock into common stock, which will be accounted for as a reverse asset acquisition with United Dogecoin as the acquirer. The report is expected within five calendar days of the filing deadline.The future of tradingShuttle Pharmaceuticals corrects pre-funded warrants issued to 9,741,751 shares as of Sept. 9Shuttle Pharmaceuticals amended its Sept. 15 Form 8-K to correct pre-funded warrants issued under Item 3.02. The earlier filing cited up to 16,932,508 warrants, but as of Sept. 9, 2026, only 9,741,751 had been issued.TradingViewShuttle Pharmaceuticals Holdings, Inc. Q2 2026: Revenue $0 Net loss $(3.15M), EPS $(3.10) — 10-Q SummaryShuttle Pharmaceuticals Holdings reported Q2 2026 revenue of $0 and a net loss of $3.15 million, with diluted EPS of $(3.10), improving from a $3.71 million loss and $(32.91) EPS in the prior quarter. The company is pivoting from clinical development to AI and digital infrastructure, having acquired Molecule.ai assets and completed a merger with United Dogecoin.Investing.comShuttle Pharmaceuticals shareholders approve merger proposals and company name change By Investing.comShareholders of Shuttle Pharmaceuticals Holdings approved merger proposals with United Dogecoin and a name change to United Compute Inc. The approvals cover new share issuances up to 17 million and an amended equity plan. The company's stock continues trading under SHPH.Investing.comShuttle Pharmaceuticals shareholders approve merger proposals and company name change By Investing.comShareholders of Shuttle Pharmaceuticals Holdings approved merger proposals with United Dogecoin Inc. and a name change to United Compute Inc. at a special meeting, with stockholders representing about 57% of shares. The proposals authorize up to 17 million new shares and an 8.8 million share increase in the equity plan.AInvestWhy Shuttle Pharmaceuticals' Late Filing Is a Signal About Its Financial PlumbingShuttle Pharmaceuticals missed its July 31 deadline to file a Form 10-Q for the quarter ended June 30, 2026, and Nasdaq issued a noncompliance notice on August 28, giving it 60 days to submit a compliance plan. The company has $1.09 million in cash, a $5.8 million working capital deficit and no revenue, and faces a September 3 shareholder vote on a $9.55 million PIPE financing that could dilute holders by tens of millions of shares.YahooShuttle Pharmaceuticals Holdings, Inc. Announces Receipt of NASDAQ Noncompliance LetterShuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) said on August 28, 2026 it is not in compliance with Nasdaq Listing Rule 5250(c)(1) for continued listing because it failed to file its Form 10-Q for the quarter ended June 30, 2026. The company must submit a compliance plan by October 27, 2026, and Nasdaq could grant an exception of up to 180 calendar days, until February 22, 2027.NewsfileShuttle Pharmaceuticals Holdings, Inc. Announces Receipt of NASDAQ Noncompliance LetterShuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) said on August 28, 2026 it received a Nasdaq letter stating it is not in compliance with Listing Rule 5250(c)(1) for failing to file its Form 10-Q for the quarter ended June 30, 2026. The company must submit a compliance plan by October 27, 2026, and Nasdaq could grant an extension of up to 180 calendar days, until February 22, 2027.Ticker ReportShort Interest in Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) Decreases By 86.9%Short interest in Shuttle Pharmaceuticals Holdings, Inc. decreased by 86.9% to 56,379 shares as of July 31st, while the company's stock price rose 8.3% during trading hours on a recent Thursday. Despite this market activity, analysts maintain a consensus 'Sell' rating, with Weiss Ratings recently upgrading its specific rating from 'sell (e)' to 'sell (e+)'.